Patient-reported data on the severity of Von Willebrand disease.
Von Willebrand disease
classification
disease severity
patient reported outcome measures
quality of life
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
revised:
28
08
2024
received:
20
06
2024
accepted:
08
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
aheadofprint
Résumé
The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient-reported outcomes (PROs) in VWD. The study aimed to investigate the patient-perspective on VWD severity and to identify key factors that determine the severity of disease experienced by patients. Patients participated in a nationwide cross-sectional study on VWD in the Netherlands (WiN-study). Patients filled in a questionnaire containing questions on the experienced severity of VWD (4-point scale), bleeding score (BS) and quality of life (QoL). We included 736 patients, median age of 41.0 years (IQR 23.0-55.0) and 59.5% were women. A total of 443 had type 1, 269 type 2 and 24 type 3 VWD. Self-reported severity of VWD was categorized as severe (n = 52), moderate (n = 171), mild (n = 393) or negligible (n = 120). Classification by historically lowest FVIII:C levels < 0.20 IU/mL as a proxy for severe VWD aligned with patient-reported severity classification with a 72% accuracy. Type 3 VWD (OR = 4.02, 95%CI: 1.72-9.45), higher BS (OR = 1.09, 95%CI: 1.06-1.11), female sex (OR = 1.36, 95%CI: 1.01-1.83), haemostatic treatment in the year preceding study inclusion (OR = 1.53, 95%CI: 1.10-2.13) and historically lowest VWF:Act levels (OR = 0.26, 95%CI: 0.07-1.00) were independent determinants of patient-reported severity. This study shows that patient-reported data provide novel insights into the determinants of experienced disease severity. Our findings highlight the need for studies on PROs with validated questionnaires to assess the burden of VWD.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Stichting Haemophilia
Organisme : CSL Behring
Informations de copyright
© 2024 The Author(s). Haemophilia published by John Wiley & Sons Ltd.
Références
Leebeek FW, Eikenboom JC. Von Willebrand's Disease. N Engl J Med. 2016;375(21):2067‐2080.
Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of Von Willebrand disease: a report of the Subcommittee on Von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103‐2114.
Federici AB. Clinical diagnosis of Von Willebrand disease. Haemophilia. 2004;10(4):169‐176.
Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171‐232.
Castaman G, Goodeve A, Eikenboom J. European Group on Von Willebrand D. Principles of care for the diagnosis and treatment of Von Willebrand disease. Haematologica. 2013;98(5):667‐674.
Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of Von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167(4):453‐465.
Atiq F, Blok R, van Kwawegen CB, et al. Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies. Blood. 2024;143(14):1414‐1424.
Lavin M, Aguila S, Schneppenheim S, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130(21):2344‐2353.
Leebeek FWG, Atiq F. How I manage severe Von Willebrand disease. Br J Haematol. 2019;187(4):418‐430.
Kalot MA, Al‐Khatib M, Connell NT, et al. An international survey to inform priorities for new guidelines on Von Willebrand disease. Haemophilia. 2020;26(1):106‐116.
James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of Von Willebrand disease. Blood Adv. 2021;5(1):280‐300.
Connell NT, Flood VH, Brignardello‐Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of Von Willebrand disease. Blood Adv. 2021;5(1):301‐325.
de Wee EM, Fijnvandraat K, de Goede‐Bolder A, et al. Impact of Von Willebrand disease on health‐related quality of life in a pediatric population. J Thromb Haemost. 2011;9(3):502‐509.
de Wee EM, Mauser‐Bunschoten EP, Van Der Bom JG, et al. Health‐related quality of life among adult patients with moderate and severe Von Willebrand disease. J Thromb Haemost. 2010;8(7):1492‐1499.
Atiq F, Mauser‐Bunschoten EP, Eikenboom J, et al. Sports participation and physical activity in patients with Von Willebrand disease. Haemophilia. 2019;25(1):101‐108.
Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in Von Willebrand disease with bleeding score. Blood Rev. 2007;21(2):89‐97.
de Wee EM, Sanders YV, Mauser‐Bunschoten EP, et al. Determinants of bleeding phenotype in adult patients with moderate or severe Von Willebrand disease. Thromb Haemost. 2012;108(4):683‐692.
Sanders YV, Groeneveld D, Meijer K, et al. Von Willebrand factor propeptide and the phenotypic classification of Von Willebrand disease. Blood. 2015;125(19):3006‐3013.
Hays RD, Morales LS. The RAND‐36 measure of health‐related quality of life. Ann Med. 2001;33(5):350‐357.
Van der Zee KI, Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND‐36: een handleiding. Noordelijk centrum voor gezondheidsvraagstukken; 1993:1‐23.
Ware JE Jr, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473‐483.
Ware JE. SF‐36 physical and mental health summary scales: a user's manual. Health Assessment Lab; 1994.
McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36‐item Short‐Form Health Survey (SF‐36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40‐66.
McHorney CA, Ware JE Jr, Raczek AE. The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247‐263.
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient‐reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79. doi:10.1186/1477‐7525‐4‐79
Kempers EK, van Kwawegen CB, de Meris J, et al. Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype. Haemophilia. 2022;28(2):278‐285.
Kempers EK, van Kwawegen CB, de Meris J, et al. Colorectal cancer screening in patients with inherited bleeding disorders: high cancer detection rate in hemophilia patients. J Thromb Haemost. 2023;21(5):1177‐1188.
Castaman G, Tosetto A, Rodeghiero F. Reduced Von Willebrand factor survival in Von Willebrand disease: pathophysiologic and clinical relevance. J Thromb Haemost. 2009;7(1):71‐74.
Gézsi A, Budde U, Deák I, et al. Accelerated clearance alone explains ultra‐large multimers in Von Willebrand disease Vicenza. J Thromb Haemost. 2010;8(6):1273‐1280.
Punt MC, Blaauwgeers MW, Timmer MA, Welsing PMJ, Schutgens REG, van Galen KPM. Reliability and feasibility of the self‐administered ISTH‐bleeding assessment tool. TH Open. 2019;3(4):e350‐e355.
Grimmer K, Bowman P. The effect of age and chronicity on patient recall of public hospital outpatient clinic use. Aust Health Rev. 1997;20(1):78‐87.
Wallihan DB, Stump TE, Callahan CM. Accuracy of self‐reported health services use and patterns of care among urban older adults. Med Care. 1999;37(7):662‐670.
Jenkins P, Earle‐Richardson G, Slingerland DT, May J. Time dependent memory decay. Am J Ind Med. 2002;41(2):98‐101.
De Wee EM, Knol HM, Mauser‐Bunschoten EP, et al. Gynaecological and obstetric bleeding in moderate and severe Von Willebrand disease. Thromb Haemost. 2011;106(5):885‐892.
van Hoorn ES, Houwing ME, Al Arashi W, et al. Patient‐reported outcomes in autosomal inherited bleeding disorders: a systematic literature review. Haemophilia. 2022;28(2):197‐214.
Teela L, Luijten MAJ, Kuijlaars IAR, et al. Psychometrics of the patient‐reported outcomes measurement information system measures in hemophilia: the applicability of the pediatric item banks. Res Pract Thromb Haemost. 2023;7(6):102159.
van Balen EC, Haverman L, Hassan S, et al. Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands. J Thromb Haemost. 2021;19(11):2687‐26701.
van Hoorn ES, Willems SPE, Al Arashi W, et al. Psychometrics of patient‐reported outcomes measurement information system in Von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders. Res Pract Thromb Haemost. 2024;8(4):102474.
Cuevas‐Trisan R. Balance Problems and Fall Risks in the Elderly. Clin Geriatr Med. 2019;35(2):173‐183.
Pofahl WE, Pories WJ. Current status and future directions of geriatric general surgery. J Am Geriatr Soc. 2003;51(7):S351‐S354.